Search Results temafloxacin
1.
Reporting of adverse drug events: a key to postmarketing drug safety. (FDA Perspective)
...with the anti-infective agent temafloxacin (Omniflox). On June 5, 1992...than four months on the market, temafloxacin was voluntarily withdrawn from...adverse drug events. Background Temafloxacin, approved for marketing in the...
September 1, 1992; American Family Physician
2.
Emerging Mechanisms of Fluoroquinolone Resistance.
...acceptance in hospitalized and community patients, and usage appears to be increasing (1,2). Although some members of the class (temafloxacin, grepafloxacin, and trovafloxacin) have been withdrawn or restricted because of adverse events, new members continue to be...
March 1, 2001; Emerging Infectious Diseases
3.
Abbott Sued in Texas Over Antibiotic
...antibiotic that was intended to treat a variety of infections. The drug in question is Omniflox, a trade name for the chemical temafloxacin, according to court documents. The lawsuits have been filed against Abbott Laboratories of North Chicago and allege the deaths...
August 10, 1994; Chicago Sun-Times
4.
Side effects, three deaths push Abbott to pull drug
...of severe side effects, including three deaths. The drug, temafloxacin, has been marketed as Omniflox only since Feb. 1 in the United...said. Analyst Gene Gargiulo of First Boston Corp. estimated temafloxacin would have generated $100 million to $150 million in sales...
June 6, 1992; Chicago Sun-Times
5.
Omniflox recalled. (antibiotic)
...manufacturer of a recently approved antibiotic voluntarily recalled the drug in June and halted distribution. FDA approved Omniflox (temafloxacin) tablets, manufactured by Abbott Laboratories, Abbott Park, Ill., in January 1992. By June, there were about 50 reports of...
September 1, 1992; FDA Consumer
6.
Abbott's Omniflox is approved. (Abbott Laboratories' antibiotic)
...pharmaceutical market as the result of the FDA's approval of Omniflox. The antibiotic (which is generically referred to as temafloxacin) could bring in hundreds of millions of dollars in annual sales for the company that is best known for its diagnostic equipment...
February 24, 1992; Chain Drug Review
7.
THE TICKER
...GETS FDA OK: Abbott Laboratories said Friday it received clearance from the government to market Omniflox, its trademark for temafloxacin, a new quinolone antibiotic intended to treat lower respiratory infections, especially strep pneumonia; genitourinary infections...
February 1, 1992; Chicago Sun-Times
8.
Quinolone safety and efficacy more important than potency.(Letters)(Letter to the Editor)
...efficacy. Serious adverse drug effects in patients led to the withdrawal or restriction of four quinolones in the past decade (temafloxacin, grepafloxacin, trovafloxacin, and sparfloxacin). Safety may differ substantially among the quinolones discussed in Scheld...
January 1, 2004; Emerging Infectious Diseases
9.
MedWatch: on the lookout for medical product problems. (FDA program to monitor side effects to drugs) (includes related article on reporting reactions to vaccines)
...pose a serious safety problem when the drug is used by many times that number of patients. A recent example is Omniflox (temafloxacin), an antibiotic drug first marketed in the United States in February 1992. Less than four months after its introduction into...
November 1, 1993; FDA Consumer
10.
HEALTH: SOME ANTIBIOTICS ARE THE PROBLEM, NOT THE REMEDY
...but also increased their potential toxicity to humans. Abbott Laboratories ordered a worldwide recall of its drug Omniflox (temafloxacin) in 1992 after a number of liver failures and deaths. Raxar (grepafloxacin) was recalled by maker Glaxo Wellcome in 1999...
July 26, 2004; Inter Press Service English News Wire
|
